Uproleselan
Myeloid Leukemia Associated With Down Syndrome
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Myeloid Leukemia Associated With Down Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) Children's Oncology Group | Phase 3 | B |
Mitoxantrone Children's Oncology Group | Phase 3 | B |
THIOGUANINE ANHYDROUS Children's Oncology Group | Phase 3 | B |
ETOPOSIDE Children's Oncology Group | Phase 3 | B |
Daunorubicin Children's Oncology Group | Phase 3 | B |
ASPARAGINASE Children's Oncology Group | Phase 3 | B |
Fludarabine National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Uproleselan is also rated in:
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CCC
Indicative ·
52 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →